CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet ...

ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical (CLSD), Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

- New, nonclinical data indicates potential for suprachoroidal administration of gene-based therapies - ALPHARETTA, Ga., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio ATLANTA — Clearside Biomedical has been ...

MILPITAS, Calif. & INDIANAPOLIS--(BUSINESS WIRE)--Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 1/2 ...